看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 0.6x - 0.6x | 0.6x |
| Selected Fwd EBIT Multiple | 0.6x - 0.7x | 0.6x |
| Fair Value | $5.10 - $4.90 | $5 |
| Upside | 61.5% - 55.1% | 58.3% |
| Benchmarks | Ticker | Full Ticker |
| Yield10 Bioscience, Inc. | YTEN.Q | OTCPK:YTEN.Q |
| Dyadic International, Inc. | DYAI | NasdaqCM:DYAI |
| Onconetix, Inc. | ONCO | NasdaqCM:ONCO |
| Geron Corporation | GERN | NasdaqGS:GERN |
| Trevena, Inc. | TRVN | OTCPK:TRVN |
| Artiva Biotherapeutics, Inc. | ARTV | NasdaqGM:ARTV |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| YTEN.Q | DYAI | ONCO | GERN | TRVN | ARTV | ||
| OTCPK:YTEN.Q | NasdaqCM:DYAI | NasdaqCM:ONCO | NasdaqGS:GERN | OTCPK:TRVN | NasdaqGM:ARTV | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| Latest Twelve Months | 11.1% | 28.2% | -0.2% | 10.4% | 6.9% | -119.4% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -3617.9% | -441.2% | -7788.4% | -24589.2% | -15325.1% | -4427.9% | |
| Prior Fiscal Year | -2989.1% | -282.6% | NA | -81832.9% | 13486.8% | -91.6% | |
| Latest Fiscal Year | -24028.3% | -168.2% | -27161.9% | -225.6% | -1129.2% | -26805.6% | |
| Latest Twelve Months | -1679.1% | -168.2% | -735.2% | -225.6% | -5880.0% | -26805.6% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.72x | 10.40x | 9.43x | 8.72x | 46.12x | -374.85x | |
| EV / LTM EBITDA | -0.2x | NA | -1.3x | -3.9x | -0.8x | 1.5x | |
| EV / LTM EBIT | -0.2x | -6.2x | -1.3x | -3.9x | -0.8x | 1.4x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -6.2x | -1.3x | -0.2x | ||||
| Historical EV / LTM EBIT | 1.4x | 1.4x | 1.4x | ||||
| Selected EV / LTM EBIT | 0.6x | 0.6x | 0.6x | ||||
| (x) LTM EBIT | (67) | (67) | (67) | ||||
| (=) Implied Enterprise Value | (38) | (40) | (42) | ||||
| (-) Non-shareholder Claims * | 171 | 171 | 171 | ||||
| (=) Equity Value | 133 | 131 | 129 | ||||
| (/) Shares Outstanding | 24.4 | 24.4 | 24.4 | ||||
| Implied Value Range | 5.46 | 5.38 | 5.30 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 5.46 | 5.38 | 5.30 | 3.16 | |||
| Upside / (Downside) | 72.9% | 70.3% | 67.7% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | YTEN.Q | DYAI | ONCO | GERN | TRVN | ARTV | |
| Enterprise Value | 2 | 36 | 18 | 672 | 25 | (94) | |
| (+) Cash & Short Term Investments | 1 | 9 | 0 | 407 | 13 | 185 | |
| (+) Investments & Other | 0 | 0 | 0 | 95 | 0 | 0 | |
| (-) Debt | (3) | (5) | (10) | (122) | (38) | (14) | |
| (-) Other Liabilities | 0 | 0 | (7) | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 0 | 41 | 1 | 1,051 | 1 | 77 | |
| (/) Shares Outstanding | 0.7 | 29.6 | 8.3 | 636.9 | 0.9 | 24.4 | |
| Implied Stock Price | 0.02 | 1.37 | 0.09 | 1.65 | 1.25 | 3.16 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.02 | 1.37 | 0.09 | 1.65 | 1.25 | 3.16 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |